Eisai Co., Ltd. and Biogen Inc. announced that the European Commission (EC) has granted marketing authorization (MA) for Leqembi® (lecanemab), a m...
Pfizer Inc. announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) vote...
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd announced a settlement and license agreement...
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild de...
Certara, Inc. a global leader in model-informed drug development, announced the launch of its Non-Animal Navigator™ solution designed to help bi...
ACRO Biomedical Co., announced that its ABCcolla® Collagen Ophthalmic Matrix has received regulatory approval from Taiwan's&n...
Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThe...
Sandoz , the global leader in generic and biosimilar medicines, announced the filing of an antitrust lawsuit in the US against Amgen, Inc. (Amgen),...
AbbVie announced that the European Commission (EC) granted marketing authorization to RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment ...
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy®...
GC Biopharma announced 09. Apr. 2025 that the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine, BARYTHRAX, jointly develop...
Halozyme Therapeutics, Inc.announced that Janssen-Cilag International NV, a Johnson & Johnson company, has received European Commission (EC) mark...
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the European Union (EU) for the treatment of adult...
Pillar Biosciences, Inc., the leader in Decision Medicine™, announced they have received nationwide Medicare coverage by the Centers fo...
© 2025 Biopharma Boardroom. All Rights Reserved.
